📊 AI Stock Rating — Summary

Insmed Incorporated reported a quarterly revenue of $142.34 million with a net loss of $370.02 million and an EPS of -$1.75. Free cash flow was negative at -$222.18 million. Year-over-year growth figures indicate that revenue rose modestly, but profitability remains elusive. Insmed's balance sheet reflects total assets of $2.36 billion against liabilities of $1.42 billion, resulting in an equity of $945.57 million and a net cash position indicating significant financial flexibility. Despite ongoing net losses, liquidity remains supported by $334.76 million in cash. With no dividends paid and no recent repurchase activity, the company focuses on reinvestment. Analyst price targets, reaching up to $225, suggest potential stock appreciation. However, profitability challenges and negative cash flow are critical focal points for future performance.

AI Score Breakdown

Revenue Growth — Score: 6/10

Revenue growth is modest but stable, reflecting the company's focus on expanding market penetration. Continued investment in R&D and product pipeline development remains the main driver, although this comes at a high cost given the substantial net loss.

Profitability — Score: 3/10

Insmed struggles with profitability, highlighted by a net income of -$370.02 million and an EPS of -$1.75. High R&D expenses impact operating efficiency and margins, leading to sustained losses and challenges in reaching breakeven.

Cash Flow Quality — Score: 4/10

Negative free cash flow of -$222.18 million reflects cash burn from operational activities. While no dividends or buybacks occurred, maintaining substantial cash reserves provides some financial stability.

Leverage & Balance Sheet — Score: 7/10

The company's balance sheet shows robust financial resilience with total equity of $945.57 million and a net debt position indicating more cash than debt. This suggests a strong capacity to sustain operations and explore growth opportunities.

Shareholder Returns — Score: 5/10

Insmed does not currently pay dividends or engage in share repurchases. Stock price movements will primarily drive shareholder value. Analyst targets suggest upside potential, but negative short-term price changes weigh on returns.

Analyst Sentiment & Valuation — Score: 5/10

Analyst price targets ranging from $180 to $225 indicate mixed sentiment with potential appreciation. Current profitability issues and negative free cash flow weigh on valuation assessments, though potential pipeline successes could improve future prospects.

⚠ AI-generated — informational only, not financial advice.